References
1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma.Pathology. 2018;50(1):74-87.
2. Yokoyama A. Molecular mechanisms of MLL-associated leukemia.Int J Hematol. 2015;101(4):352-361.
3. Shafer D, Wu H, Al-Saleem T, et al. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature.Arch Dermatol. 2008;144(9):1155-1162.
4. Takachi T, Iwabuchi H, Imamura M, Imai C. Lymphoblastic lymphoma with mature B-cell immunophenotype and MLL-AF9 in a child. Pediatr Blood Cancer. 2011;57(7):1251-1252.
5. Quigg TC, Haddad NG, Buchsbaum JC, Shih CS. Hypothalamic obesity syndrome: rare presentation of CNS+ B-cell lymphoblastic lymphoma.Pediatr Blood Cancer. 2012;59(5):930-933.
6. Ahlmann M, Meyer C, Marschalek R, et al. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma. Eur J Haematol. 2014;93(4):349-353.
7. Larish AM, Dolan M, Casey T, Perkins JL. Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy. J Pediatr Hematol Oncol. 2015;37(4):e215-217.
8. Thandla S, Alashari M, Green DM, Aplan PD. Therapy-related T cell lymphoblastic lymphoma with t(11;19)(q23;p13) and MLL gene rearrangement. Leukemia. 1999;13(12):2116-2118.
9. Gindin T, Murty V, Alobeid B, Bhagat G. MLL/KMT2A translocations in diffuse large B-cell lymphomas. Hematol Oncol.2015;33(4):239-246.
10. Hiroki H, Yoshimi A, Kato K, Yanai T, Koike K. Primary Cutaneous Diffuse Large B-Cell Lymphoma With KMT2A-MLLT3: An Infantile Case Study.J Pediatr Hematol Oncol. 2019;41(8):657-658.
11. Yan W, Jiang X, Wang W, et al. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues. Front Oncol.2020;10:803.
12. Hirabayashi S, Ohki K, Nakabayashi K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.Haematologica. 2017;102(1):118-129.
13. Hyrenius-Wittsten A, Pilheden M, Sturesson H, et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nat Commun. 2018;9(1):1770.
14. Tsutsumi S, Taketani T, Nishimura K, et al. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res. 2003;63(16):4882-4887.
15. Tsurusawa M, Mori T, Kikuchi A, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer. 2014;61(7):1215-1221.
16. Takahashi H, Kajiwara R, Kato M, et al. Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16. Int J Hematol.2018;108(1):98-108.
17. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature.2006;442(7104):818-822.
18. Forsberg EC, Prohaska SS, Katzman S, Heffner GC, Stuart JM, Weissman IL. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet. 2005;1(3):e28.
19. Jansen MW, Corral L, van der Velden VH, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia.2007;21(4):633-641.
20. Andersson AK, Ma J, Wang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.Nat Genet. 2015;47(4):330-337.